Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Historical Holders from Q1 2018 to Q3 2025

Symbol
CUE on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
43.4M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
18.1M
Holdings value
$13M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
52
Number of buys
14
Number of sells
-16
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Bleichroeder LP 9.99% 0% $5.27M 6.13M 0% Bleichroeder LP 19 Mar 2025
STROME MARK E 4.99% $1.86M 2.17M Mark E. Strome 14 Nov 2022
Slate Path Capital LP 1.4% $790K 919K Slate Path Capital LP 31 Dec 2024

Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 18.1M $13M +$520K $0.72 52
2025 Q2 17.4M $11.9M +$3.98M $0.68 46
2025 Q1 11.4M $10.4M -$452K $0.91 49
2024 Q4 11.8M $12.8M -$1.53M $1.09 55
2024 Q3 13.9M $10.5M -$289K $0.76 50
2024 Q2 13.8M $17.1M -$3.73M $1.24 72
2024 Q1 16.4M $31M +$2.72M $1.89 74
2023 Q4 14.9M $39.3M +$2.54M $2.64 80
2023 Q3 14M $32.1M -$635K $2.30 75
2023 Q2 13.8M $50.5M +$6.69M $3.65 77
2023 Q1 12.1M $43M -$2.54M $3.57 62
2022 Q4 12.8M $36.4M +$156K $2.85 60
2022 Q3 12.8M $28.7M -$3M $2.23 61
2022 Q2 14.1M $35M -$11M $2.49 68
2022 Q1 17.8M $87M +$4.49M $4.88 97
2021 Q4 16.5M $187M -$11.1M $11.31 88
2021 Q3 16.9M $246M -$24M $14.57 87
2021 Q2 18.6M $216M -$2.77M $11.65 89
2021 Q1 18.8M $230M -$6.45M $12.20 88
2020 Q4 19.3M $242M -$3.02M $12.51 94
2020 Q3 19.5M $294M +$50M $15.05 90
2020 Q2 16M $393M +$85M $24.51 99
2020 Q1 13M $185M +$36.6M $14.19 72
2019 Q4 10.6M $168M +$63.1M $15.88 60
2019 Q3 6.08M $51.3M +$13.3M $8.43 44
2019 Q2 4.5M $40.5M +$10M $8.99 36
2019 Q1 3.45M $26.7M +$1.83M $7.73 37
2018 Q4 3.23M $15.2M -$2.04M $4.70 34
2018 Q3 3.58M $32.4M +$3.24M $9.05 36
2018 Q2 3.15M $37.3M +$15.4M $11.86 37
2018 Q1 1.84M $25.9M +$25.9M $14.05 28